EvidenceLib · Open textbook · CC BY 4.0
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Nigel Fleeman, Rachel Houten, Adrian Bagust, Marty Richardson, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Juliet Hounsome, Rui Duarte, Aditya Shenoy · 9 sections in 9 chapters. Each section is its own page.
Background
Definition of the decision problem
Methods for reviewing clinical effectiveness literature
Findings from the systematic review of clinical effectiveness literature
Assessment of cost-effectiveness
Discussion
Conclusions
References
Acknowledgements
Attribution. Nigel Fleeman; Rachel Houten; Adrian Bagust; Marty Richardson; Sophie Beale; Angela Boland et al. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2020. This work was produced by Fleeman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK552390. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.